anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bisoprolol fumarate should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of bisoprolol fumarate tablets may produce excessive reduction of sympathetic activity. In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that bisoprolol fumarate tablets be discontinued for several days before the withdrawal of clonidine.

Bisoprolol fumarate should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists [particularly of the phenylalkylamine (verapamil) and benzothiazepine (diltiazem) classes], or antiarrhythmic agents, such as disopyramide, are used concurrently.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, resulting in a shortened elimination half-life of bisoprolol fumarate. However, initial dose modification is generally not necessary. Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. There was no effect of bisoprolol fumarate on prothrombin time in patients on stable doses of warfarin.

Risk of Anaphylactic Reaction

While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use useful for improving the chapped skin caused by an allergic reaction, an extraneous fungus, drying or the like by making the preparation include a specific mono-cis- alkenecarboxylic acid and specified ceramides in specific amounts. SOLUTION: This preparation for external use is obtained by including (A) 1-10 wt.% of cis-6-hexadecenoic acid and (B) 0.1-10 wt.% of ceramides or a substance having a ceramide analogous structure. The ingredient A is especially preferably formulated in an amount of 1-5 wt.% and the ingredient B is especially preferably formulated in an amount of 0.1-5 wt.%. The weight ratio of the ingredients A:B is preferably (100:1) to (1:10), especially preferably (10:1) to (1:10). The pH of the preparation for external use is preferably 2-6.9, especially preferably 3-6.5 for application to the skin showing atopic dermatitis. The ingredient A can be prepared by a well-known metathetic reaction or a method of using a microorganism but may be extracted from Thunbergia alata which is a liana for use. A natural ceramide, a sphingosine derivative and the like are cited as the ingredient B.
Lorazepam, a benzodiazepine with antianxiety and sedative and anticonvulsant effects, is intended for intramuscular or intravenous route of administration. It has the chemical formula 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one. The molecular weight is 321.16, and the C.A.S. No. is [846-49-1]. The molecular formula is C15H10Cl2N202. The structural formula is:

Lorazepam is a nearly white powder almost insoluble in water. Each mL of sterile injection contains either 2 or 4 mg of lorazepam, 0.18 mL polyethylene glycol 400 in propylene glycol with 2% benzyl alcohol as preservative.
One Omega-3 fatty acid softgel capsule 1 gm for children at or below 25 kg and two Omega-3 fatty acid softgel capsule above 25 kg. In this intervention arm having 32 participants, half will have plasma Omega 3 fatty acid level within reference value and rest half below reference value.
FIELD: medicine, preparative biochemistry. SUBSTANCE: method for purification of rDSPA α1 from biological medium involves the following stages: (a) applying biological medium on cation-exchange resin at pH 5; (b) washing out cation-exchange resin with pH 5 with 100 mM of NaOAc and 50 mM sodium phosphate with pH 7.5; (c) elution of bound rDSPA α1 from cation-exchange resin with buffer containing 50 mM of sodium phosphate and 500 mM of sodium chloride with pH 7.5; (d) applying eluent from stage (c) containing rDSPA α1 at pH 4 on hydrophobic-interacting resin; (e) washing out hydrophobic-interacting resin with 20 mM of HCl and then with 20 mM HCl containing 19% of ethanol; (f) elution of bound rDSPA α1 from hydrophobic-interacting resin with buffer containing 29% of ethanol and 20 mM of HCl at pH 2.5; (g) applying eluent from stage (f) containing rDSPA α1 at pH 2.5 on resin for carrying out affinity chromatography; (h) washing out resin for affinity chromatography with 20 mM HCl; (i) elution of bound rDSPA α1 from resin for affinity chromatography with buffer containing 200 mM of glycine at pH between 4 and 5 to obtain essentially pure rDSPA α1 in an aqueous solution. Recombinant rDSPA α1 is prepared by purification method indicated above. Pharmaceutical composition for therapy of arterial and venous thrombosis contains effective amount of rDSPA α1 prepared by purification method indicated above. Invention allows isolation and purification of rDSPA α1 in industrial scale with purity degree providing preparing pharmaceutical preparations. EFFECT: improved preparing method, valuable medicinal properties of activator. 6 cl
Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
On the first full inpatient day (Day 1), participants will smoke one specified strength (Dose A) of cannabis. Days 2-8 will comprise Phase 1, in which a second strength (Dose B) of cannabis will be administered 3x/day. The next 7 days (Day 9-15) will be Phase 2, in which cannabis Dose A will be administered once again, at the same 3 daily time points.
We will conduct a randomized, double-blind trial using a stepped-wedge design and involving a total of 60 patients with stable treated HIV and suppressed viral load who will all receive the BCG vaccine during the course of the study. Patients will be divided into two groups of equal size (early and late groups regarding administration of the BCG verum). The trial will be placebo-controlled and double-blind. Patients in the early group will receive the BCG verum at the beginning of Treatment Phase 1, and then the placebo at the beginning of Treatment Phase 2.
The study will be conducted at the A. R. Kaufman YMCA fitness center where 32 registrants of the "Move for Health Program" (formally known as the Live Smart program) will be asked to participate. The "Move for Health" program is a 12-week, twice-weekly 60 minute program that includes both aerobic and strength training. The cognitive training (delivered by an Android Tablet) focuses on dual-task training and requires participants to employ higher-order cognitive abilities such as attention and executive function. 16 Participants in one group will complete cognitive training integrated into the Move for Health exercise program, whereas 16 participants in the other group (completing program on separate days) will complete the exercise program only. All participants will complete assessments of cognitive function, physical function, well-being, and self-efficacy before and after the programs. This study will be the first to examine the feasibility, acceptability, and effectiveness of a combined cognitive and exercise training program for older adults in a community-setting. If shown to be feasible, it has the potential for broader investigation and, eventually, wide-scale implementation to benefits the health of older Canadians.

Note: Due to low recruitment rates, 11 participants were recruited in the Fall of 2019 and all completed the experimental intervention. 32 participants were recruited and randomized for the Winter of 2020. In response to COVID-19, the YMCA shut down and thus the intervention has halted prematurely after 6 weeks of program. Post-program updated demographic information, activity questionnaires (physical, cognitive, and social), and assessments for overall well-being and self-efficacy will be conducted over phone or video call.
The first appointment will be performed similar to the conventional RCT group. In the second appointment, after anesthetizing with 3% mepivacine, the canals will be re-entered and irrigated well with 17% EDTA. Bleeding will be induced by inserting sterile #25 K-file into the 2-3 mm beyond the apical foramen into periapical tissues.
16 in- or outpatients with DSM-IV-TR schizophrenia or schizoaffective disorder and prominent negative symptoms will be recruited for this study. This study will consist of a randomized trial of D-serine (60 mg/kg/d) vs. placebo using a crossover design with a 2-week baseline lead-in, and two 6-week intervention arms separated by a two week, placebo controlled washout period. Biomarkers will be assessed at baseline for each treatment arm, acutely (day 7) following treatment initiation, and following 6 weeks of treatment (6 biomarker sessions total). Primary biomarker outcome measures will include 1) amplitude of the mismatch negativity (MMN) waveform and 2) amplitude of the visual P1 potential. Symptomatic outcome measures will include PANSS and composite score of the MATRICS neuropsychological battery. The study will be supported from ongoing NIMH-funded Cooperative Drug Development Grant (CDDG) to the PI.
BACKGROUND: Diabetes is a global health problem whose common complication is diabetic cardiomyopathy, characterized by chronic inflammation of the heart muscle. Macrophages are the main white blood cells found in the resting heart. Therefore, we investigated the underling mechanism of macrophage on myocardial fibrosis in diabetes.
METHODS: Here, echocardiography was utilized to evaluate cardiac function, and the degree of myocardial fibrosis was assessed using Masson's trichrome staining, followed by single-cell RNA sequencing (scRNA-seq) to analyze the phenotype, function, developmental trajectory, and interactions between immune cells, endothelial cells (ECs), and fibroblasts (FBs) in the hearts of db/db mice at different stages of diabetes. Macrophages and cardiac fibroblasts were also co-cultured in order to study the signaling between macrophages and fibroblasts.
RESULTS: We found that with the development of diabetes mellitus, myocardial hypertrophy and fibrosis occurred that was accompanied by cardiac dysfunction. A significant proportion of immune cells, endothelial cells, and fibroblasts were identified by RNA sequencing. The most significant changes observed were in macrophages, which undergo M1 polarization and are critical for oxidative stress and extracellular matrix (ECM) formation. We further found that M1 macrophages secreted interleukin-1β (IL-1β), which interacted with the receptor on the surface of fibroblasts, to cause myocardial fibrosis. In addition, crosstalk between M1 macrophages and endothelial cells also plays a key role in fibrosis and immune response regulation through IL-1β and corresponding receptors.
CONCLUSIONS: M1 macrophages mediate diabetic myocardial fibrosis through interleukin-1β interaction with fibroblasts.
INTRODUCTION: Aneurysmal sac regression is a predictor of long-term outcomes after endovascular aneurysm repair (EVAR). This study aimed to compare a large cohort of TREO and non-TREO endografts over a mid-term follow-up and compare abdominal aortic aneurysm sac regression. The hypothesis was that TREO endografts have an increased sac regression by 24 mo.
METHODS: This is a retrospective analysis of all EVARs completed at a single institution between 2015 and 2024. Clinical and imaging data were collected from an institutional database and patients' records. The analysis included all TREO and age, sex, anticoagulation use and current smoking-matched non-TREO endografts that satisfied anatomic indications for use of the TREO graft. The primary outcomes were sac regression at 12 and 24 mo, and secondary outcomes were rates of mortality, endoleak, and reintervention.
RESULTS: Twenty-one TREO grafts were matched to 68 non-TREO grafts. The groups were similar in demographics, comorbidities, and preoperative anatomy. Preoperative abdominal aortic aneurysm sac size was larger in the TREO cohort. The mean reduction in sac size in mm was greater in the TREO cohort compared to the non-TREO cohort (-12.6 ± 8.95 versus -7.83 ± 7.74 mm, P = 0.039) over the study period. Cox regression analysis identified the TREO stent graft to be associated with 1-y sac regression (hazard ratio = 2.42, P = 0.019). The incidence of all-cause endoleaks, reintervention, and mortality were similar between cohorts.
CONCLUSIONS: These findings suggest that the TREO endograft offers better mid-term outcomes with respect to sac regression with no differences in the incidence of endoleak, mortality, or reintervention.
An herbal water beverage containing hemp preferably includes water, sugar, organic flavoring, vitamins, and hemp oil. Organic hemp seed oil is added to a water based solution of organic gum arabic and organic maltodextrin. The solution is homogenized and then spray dried. During the drying process the hemp seed oil is surrounded by a matrix of maltodextrin and gum arabic that protects it from exposure to air (oxidation). The water is removed in a dryer through evaporation leaving hemp oil droplets surrounded by a film of gum arabic and maltodextrin matrix. The gum arabic acts as an emulsifier, retarding the separation of the hemp seed oil once it is added to the water, sugar, organic flavoring, and vitamins to form the finished aqueous beverage.
One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
PURPOSE: Salvage surgery is mandatory when regional persistence/recurrence after chemoradiation. The aim of this study is to describe the outcomes of salvage surgery.
METHODS: A retrospective study was conducted in patients with locally advanced head and neck squamous cell carcinoma that were primarily treated with chemorradiation and underwent salvage neck dissection (ND) with suspected recurrent/persistent nodal disease. All patients had a response evaluation at 12 weeks through clinical examination and computed tomography-positron emission tomography. Decision for ND was taken in case of suspected persistence or if there was suspicion of recurrence, histologically confirmed.
RESULTS: There were 40 patients included. 32/40 (80%) ND were done because of confirmed/suspected persistence and 8/40 (20%) were done because of recurrences. Persistence was confirmed histologically in 14/32 (43.8%) cases and recurrence in 6/8 (75%) cases. Median survival from diagnosis was 39 months (95% CI 28.162-49.838). Significant differences were observed between patients who had viable tumour cells in the sample and those who did not, but the differences were only significant when only deaths due to tumour progression were considered (p = 0.014). 14/32 (43.8%) patients with suspected or confirmed persistence developed a recurrence after the ND and 3/8 (37.5%) patients with suspected or confirmed recurrence developed a new recurrence. New recurrences were more frequent in cases that had viable tumor in the specimen.
CONCLUSIONS: Patients with nodal persistence/recurrence have a poor prognosis, even after salvage surgery. However, in a substantial number of patients the disease is controlled after ND, so it should be offer to these patients.
Patients of 3 months to 18 years of age at the time of enrolment who have unexplained transaminase elevation (serum alanine aminotransferase (ALT) levels \> 1.5 times the upper limit of normal) for more than 3 months and/or unexplained hepatomegaly or hepatosplenomegaly and/or obesity- unrelated hepatosteatosis and/or biopsy-proven cryptogenic fibrosis and cirrhosis and/or liver transplantation for cryptogenic cirrhosis will be included.

Potential participants will be invited for LAL enzyme analysis. Written informed consent will be obtained from the parents or guardians of the participants at the time of enrolment. Prospective and retrospective data will be collected. Complete family and medical history, physical examination and previously existing laboratory findings will be recorded on standard case reports form and up to 0.25 ml of blood will be drawn for LAL enzyme analysis. The blood obtained from participants will be spotted on filter paper, and dried blood spot sample (DBS) will be prepared. Finally, the dried blood spot sample will be sent to reference laboratory (NHS Greater Glasgow and Clyde, England) for LAL enzyme measurement within 1 week.
When a person has surgery, there are a few different standard care options for pain relief. Anesthetic (numbing) drugs can be used to cause a loss of feeling in or around a wound but the effect of the numbing medication can be undone.Pain relieving drugs such as acetaminophen (Tylenol), non-steroidal anti-inflammatory drugs (NSAIDs), and opioid (narcotic) medications can also be taken by mouth or through a vein in your arm (intravenous IV.) However, both NSAIDs \& Opioid drugs can produce negative side effects such as serious difficulty breathing, stopping breathing altogether, low blood pressure, nausea, vomiting, itching, and constipation.

Bupivacaine is one of the commonly used longer-acting numbing medicines (anesthetics). The effect of Bupivacaine or other anesthetics is limited to usually no more than 12 hours when injected around the area of the incision during surgery. Liposomal Bupivacaine (Exparel) could provide good, continuous and longer pain relief than current therapies/treatments commonly used. This can possibly improve patient satisfaction and time to normal activities such as walking.
The invention discloses a preparation method for a pharmaceutical with throat clearing efficacy. The pharmaceutical is prepared by the following raw materials by weight: Gentiana futtereri, Sapindus, Tibet calamus, ligularia achyrotricha, s.moorcroftiana, Cuminum cyminum L, travertine, Solms-laubachia pulcherrima, fructus hippophais, Eriophyton wallichii, and Tibet Shikonin. The mixed smashing method or the water extracting and alcohol precipitating method or alcohol extracting and water precipitating method is used for preparing the active components. Any one common oral dosage form can be prepared. The pharmaceutical has the efficacy of diminishing inflammation and relieving a cough, promoting the circulation of qi and reducing phlegm, and clearing throat. The pharmaceutical can be used for the respiratory diseases, such as cough, swollen sore through, hoarseness, acute and chronic pharyngitis, and acute and chronic bronchitis concurrent infection.
A standard no "feedback" defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur.
Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
A health-care preparation simultaneously with magnesium supplement and antioxidant functions and a preparation method thereof are disclosed. The health-care preparation comprises a main active ingredient of magnesium agent and an excipient. The magnesium agent is MgH 2  micro-nano powder, and the excipient is a commonly used dietary supplement auxiliary material. Compared with the existing magnesium-supplementing preparation, the health-care preparation can simultaneously supplement magnesium which is the essential trace element in human body, and hydrogen which can neutralize oxygen free radicals. The present invention has the following advantages: it is convenient for storage and taking, and has a high conversion and absorption efficiency, a low cost, and no toxic side effects. Long-term use of the preparation can effectively prevent a variety of adverse symptoms caused by magnesium deficiency, moreover the introduction of hydrogen which has an antioxidant effect can benefit to anti-inflammatory, body health, anti-aging and prevention of disease.
The present invention provides methods for inhibiting or blocking TGF-.beta.  activity in cells and/or tissues expressing TGF-.beta. comprising, contacting cells and/or tissues expressing TGF-.beta.  with an amount of cholesterol or cholesterol derivative effective to inhibit the activity of TGF-.beta.. The present invention further provides a method for treating a condition associated with overactivity of TGF-.beta. or negative regulation in normal physiology by TGF-.beta. in a subject in need of treatment, comprising contacting cells and/or tissue overexpressing TGF-.beta. in the subject with an amount of cholesterol or cholesterol derivative effective to inhibit activity of TGF-.beta. thereby treating the condition. In a preferred embodiment, the cholesterol derivative is oxidized 7-DHC.
The investigators designed a prospective, investigator-initiated, single-center, single-blinded, randomized controlled study with two experimental groups. A total of 1438 participants with hospitalized patients will be enrolled and randomized into two groups; intervention or usual-care groups. The investigators will apply an AKI prediction model based on the patient's demographic. The investigators will collect data on vital signs, laboratory test results, medication history, and surgical records. The investigators provide information on whether AKI develops within 48 hours and the top 10 explanatory factors for predicting AKI to the physician. The intervention group receives the prediction results daily until the patient is discharged or up to 7 days after admission. The usual-care group does not receive analysis results.